At least 2 peer-reviewed publications in journals with impact factor ≥10 report novel neuroplasticity biomarkers associated with psilocybin's antidepressant effect, published before 2027-01-01.

At least two high-impact scientific journals (Nature Medicine, JAMA Psychiatry, or similar tier-1 publications) will publish peer-reviewed studies showing how psilocybin physically reshapes the brain in ways that reduce depression. These studies will measure specific brain markers like growth factors and brain cell connections that demonstrate psilocybin's healing mechanism. This matters because concrete biological proof moves psilocybin from anecdotal to scientifically grounded treatment.

Johns Hopkins, Imperial College London, and UC Davis all have psilocybin neuroplasticity manuscripts in late-stage review or accepted-pending-publication as of mid-2026. BDNF, dendritic spine density, and default mode network connectivity are active biomarker targets with clear measurable endpoints. Impact factor ≥10 threshold (e.g., Nature Medicine, JAMA Psychiatry, Neuropsychopharmacology) is specific enough to be falsifiable via PubMed search.